University of Pennsylvania

Cephalon, Inc.

Other

University of Illinois

Colorado State University Research Foundation

The Children's Hospital of Philadelphia

The Wistar Institute

Mark I Greene

Ramachandran Murali

Hongtao Zhang

Alan Berezov

Zheng Cai

Zhiqiang Zhu

Douglas B Cines

William Valentine Williams

Qingdu Liu

Jinqiu Chen

Mark Richter

Xin Cheng

Jeffrey A Cohen

David B Weiner

James H Eberwine

Raphael M Ottenbrite

Masahiko Kinosaki

Janet Estee Kacharmina

Xiaomin Song

Masahide Tone

James G Davis

Akihiro Hasegawa

Robert M Williams

Thomas Kieber-Emmons

Donald O'Rourke

Yingxin Xiao

Bin Li

Xin Zhang

Byeong-Woo Park

Yan Xiao

Hong Tao Zhang

Lian Lam

Michael S Kahn

George Cotsarelis

Qiang Wang

Wayne W Hancock

Roland E Baron

Natalie Minkovsky

Hiromichi Tsuchiya

Geng Zhang

Yasuhiro Nagai

Aaron Runkle

Jeffrey Drebin

Mei Qing Ji

Makoto Katsumato

William Carle Horne

Kazuhiro Aoki

Wataru Takasaki

Horacio U Saragovi

Yingxin Xiaio

Junji Hamuro

Kunio Dobashi

Makoto Katsumata

Xiaolan Qian

Jeffrey A Drebin

Qindu Liu

Ramchandran Murali

Donald M O'Rourke

Yashuiro Nagai

Raphaele Ottenbrite

Ramachandran Muralli

Provided herein are isolated antibodies or antibody fragments thereof that immunospecifically bind to platelet factor 4 (PF4). In some embodiments the isolated antibodies or antigen-binding fragments thereof comprise a light chain CDR and framework region comprising SEQ ID NO: 4 and a heavy chain CDR and framework region comprising SEQ ID NO: 10. Also provided herein are methods for treating heparin-induced thrombocytopenia (HIT) and methods for reducing the likelihood that subject will become afflicted with HIT. Further disclosed are uses of the isolated antibodies or antibody fragments in the treatment of HIT or the manufacture of compositions for the treatment of HIT.

Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia

The present invention provides a mutant protein which has the same amino acid sequence of a wild type PF4 monomer except that (i) at least one amino acid of the wild type PF4 monomer has been deleted, (ii) at least one amino acid of the wild type PF4 monomer has been replaced by another amino acid, or (iii) a combination of such changes has been made. The present invention also provides methods of treating or reducing the likelihood of HIT, treating angiogenesis, treating abnormal cell growth, or affecting coagulation pathologies that lead to thrombus formation, by administering such mutant proteins to a patient.

Atomic description of immune complex that causes heparin-induced thrombocytopenia

The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants. The present invention also provides a mutant protein which has the same amino acid sequence of a wild type PF4 monomer except that (i) at least one amino acid of the wild type PF4 monomer has been deleted, (ii) at least one amino acid of the wild type PF4 monomer has been replaced by another amino acid, or (iii) a combination of such changes has been made. The present invention also provides methods of treating or reducing the likelihood of HIT, treating angiogenesis, treating abnormal cell growth, or affecting coagulation pathologies that lead to thrombus formation, by administering such mutant proteins to a patient.

Disclosed herein are methods of increasing response to radiation therapy in subjects afflicted with cancer. In some embodiments, the method comprises reducing the ability of an immune suppressor cell (e.g., MDSC) to migrate to the microenvironment of the cancer. In some embodiments, the method further comprises suppressing the migration of the immune suppressor cell to a non-malignant cell and/or suppressing the malignant transformation of the non-malignant cells.

Methods of increasing response to cancer radiation therapy

Disclosed herein are multifunctional antigen-binding proteins comprising at least one multifunctional recombinant protein scaffold and at least one antigen-specific binding domain. Polynucleotides encoding the multifunctional antigen-binding proteins, vectors containing the disclosed polynucleotides, and cells that have been genetically engineered to express the polynucleotide are also provided. Methods of using the multifunctional antigen-binding proteins are disclosed.

IgG binding peptides and multifunctional antigen-binding proteins comprising the same

Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Antigen-binding proteins comprising recombinant protein scaffolds

The present invention relates to compounds of formula (I) that are inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-&#x3b1; mediated conditions: Formula (I)

Inhibitors of the tumor necrosis factor receptor complex

This invention is in the fields of immunology and autoimmunity. More particularly it concerns pharmaceutical compositions comprising compounds which are useful agents for inhibiting the functions of TIP60 and the use of such compounds in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases.

TIP60 inhibitors

This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for inhibiting cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, and methods for treating these disorders.

Methods and use of bifunctional enzyme-building clamp-shaped molecules

This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for treating cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, particularly for expanding the efficacy of drugs previously developed for this purpose, and for methods of treatments using the compounds for this purpose.

Mutation mimicking compounds that bind to the kinase domain of EGFR

This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor.

Methods and use of compounds that bind to HER2/neu receptor complex

Growing community of inventors

Penn Valley, PA, United States of America

Mark I Greene